EAA172 – A Phase I/II Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status
Physician and Research Staff Educational Materials:
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
- Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.
Information and Assistance from the National Cancer Institute:
- Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.
Additional Information on Cancer.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit clinicaltrials.gov and search for record NCT03701321.